Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
HAYWARD, Calif., Sept. 06, 2017 -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy, announced today that Craig Thompson, President & Chief Executive Officer, will present a corporate update at Rodman & Renshaw’s 18th Annual Global Investment Conference.
The presentation will be at 10:25 AM ET, September 12th, at the Lotte New York Palace Hotel in New York.
The audio portion of the presentation will be accessible through the company’s Investors page at www.anthera.com/investors following the presentation.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious and life-threatening diseases, including exocrine pancreatic insufficiency and IgA nephropathy. Additional information on Anthera can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.
Contact Information CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc. [email protected] For Media Inquiries: Srikant Ramaswami rbb Communications [email protected] 718-710-1350 www.twitter.com/antherapharma https://www.facebook.com/antherapharma/ https://www.linkedin.com/company/anthera-pharmaceuticals
